U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO2
Molecular Weight 153.1784
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOPAMINE

SMILES

NCCC1=CC=C(O)C(O)=C1

InChI

InChIKey=VYFYYTLLBUKUHU-UHFFFAOYSA-N
InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2

HIDE SMILES / InChI

Description

Dopamine, a sympathomimetic amine vasopressor, is the naturally occurring immediate precursor of norepinephrine. G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension. Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DOPAMINE HYDROCHLORIDE
PubMed

PubMed

TitleDatePubMed
[Pharmacological studies of antipsychotic drug, penfluridol. 2. General pharmacological properties].
1976 Jul
Selective substrates for non-neuronal monoamine transporters.
1999 Jul
alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine.
1999 Jun
The use of oral vasopressors in the management of autonomic dysfunction and orthostatic hypotension.
1999 May
[Distributive shock and it's therapy by cardio-vascular acting drugs].
1999 Oct
Rapid induction of behavioral and neurochemical tolerance to cocaethylene, a model compound for agonist therapy of cocaine dependence.
1999 Sep 1
Estrogen priming modulates autoreceptor-mediated potentiation of dopamine uptake.
2000 Aug 11
Repeated adenosine pre-treatment potentiates the acute effect of methamphetamine in rats.
2000 Sep
Dopamine deficiency in mice.
2000 Sep
A hypertensive reaction induced by concurrent use of selegiline and dopamine.
2000 Sep
Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats.
2001
SCH 23390 affords protection against soman-evoked seizures in the freely moving guinea-pig: a concomitant neurochemical, electrophysiological and behavioural study.
2001
Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
2001
The effects of nitric oxide on the oxidations of l-dopa and dopamine mediated by tyrosinase and peroxidase.
2001 Apr 6
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.
2001 Feb 1
Inhibition of a Gi-activated potassium channel (GIRK1/4) by the Gq-coupled m1 muscarinic acetylcholine receptor.
2001 Feb 23
Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro.
2001 Jan
Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan.
2001 Jan
Monoamine compounds in cerebrospinal fluid of healthy subjects punctured without preceding strict bed rest: a pilot study.
2001 Jan
Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease.
2001 Jan
Changes of biogenic amine levels in haemolymph during diapausing and non-diapausing status in Pieris brassicae L.
2001 Jan
The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
2001 Jan
Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent.
2001 Jan
Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence.
2001 Jan
Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.
2001 Jan
Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.
2001 Jan
A study of the binding requirements of calyculin A and dephosphonocalyculin A with PP1, development of a molecular recognition model for the binding interactions of the okadaic acid class of compounds with PP1.
2001 Jan
Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo.
2001 Jan
Regulation by the medial amygdala of copulation and medial preoptic dopamine release.
2001 Jan 1
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
2001 Jan 12
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1.
2001 Jan 12
Activation of dopamine D(1)-like receptor causes phosphorylation of alpha(1)-subunit of Na(+),K(+)-ATPase in rat renal proximal tubules.
2001 Jan 5
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
2001 Jan 5
Gyroxin fails to modify in vitro release of labelled dopamine and acetylcholine from rat and mouse striatal tissue.
2001 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Rate of Administration – Dopamine Hydrochloride Injection, USP after dilution, is administered intravenously by infusion via a suitable I.V. catheter or needle. When administering Dopamine Hydrochloride (or any potent medication) by continuous intravenous infusion, it is advisable to use a precision volume control I.V. set. Each patient must be individually titrated to the desired hemodynamic or renal response to dopamine. In titrating to the desired increase in systolic blood pressure, the optimum dosage rate for renal response may be exceeded, thus necessitating a reduction in rate after the hemodynamic condition is stabilized. Administration at rates greater than 50 mcg/kg/min have safely been used in advanced circulatory decompensation states. If unnecessary fluid expansion is of concern, adjustment of drug concentration may be preferred over increasing the flow rate of a less concentrated dilution. Suggested Regimen: 1. When appropriate, increase blood volume with whole blood or plasma until central venous pressure is 10 to 15 cm H2O or pulmonary wedge pressure is 14 to 18 mm Hg. 2. Begin infusion of diluted solution at doses of 2 – 5 mcg/kg/min of Dopamine Hydrochloride in patients who are likely to respond to modest increments of heart force and renal perfusion. In more seriously ill patients, begin infusion of diluted solution at doses of 5 mcg/kg/min of Dopamine Hydrochloride and increase gradually using 5 to 10 mcg/kg/min increments up to a rate of 20 to 50 mcg/kg/min as needed. If doses in excess of 50 mcg/kg/min are required, it is advisable to check urine output frequently. Should urinary flow begin to decrease in the absence of hypotension, reduction of dopamine dosage should be considered. Multiclinic trials have shown that more than 50 percent of patients have been satisfactorily maintained on doses less than 20 mcg/kg/min. In patients who do not respond to these doses with adequate arterial pressures or urine flow, additional increments of dopamine may be given in an effort to produce an appropriate arterial pressure and central perfusion. 3. Treatment of all patients requires constant evaluation of therapy in terms of blood volume, augmentation of cardiac contractility, and distribution of peripheral perfusion. Dosage of dopamine should be adjusted according to the patient’s response, with particular attention to diminution of established urine flow rate, increasing tachycardia or development of new dysrhythmias as indices for decreasing or temporarily suspending the dosage. 4. As with all potent intravenously administered drugs, care should be taken to control the rate of administration to avoid inadvertent administration of a bolus of the drug. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Route of Administration: Intravenous
Name Type Language
DOPAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
MEDOPA
Brand Name English
4-(2-AMINOETHYL)PYROCATECHOL
Systematic Name English
DOBUTAMINE A
Common Name English
DOPAMINE [INN]
Common Name English
DOPAMINE [VANDF]
Common Name English
DOPAMINE [WHO-DD]
Common Name English
DOBUTAMINE HYDROCHLORIDESPECIFIED IMPURITY A [EP]
Common Name English
HYDROXYTYRAMINE
Systematic Name English
DOBUTAMINE HYDROCHLORIDE IMPURITY A [EP]
Common Name English
OXYTYRAMINE
Common Name English
DOPAMINE [MI]
Common Name English
1,2-BENZENEDIOL, 4-(2-AMINOETHYL)-
Systematic Name English
NSC-173182
Code English
DOPAMINE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C88516
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
NDF-RT N0000007715
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 12.4
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
WHO-ATC C01CA04
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
NDF-RT N0000175570
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
WHO-VATC QC01CA04
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
Code System Code Type Description
MESH
D004298
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
EPA CompTox
51-61-6
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
LactMed
51-61-6
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
ECHA (EC/EINECS)
200-110-0
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
WIKIPEDIA
DOPAMINE
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
NCI_THESAURUS
C62025
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
PUBCHEM
681
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
HSDB
51-61-6
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
ChEMBL
CHEMBL59
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
RXCUI
3628
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY RxNorm
MERCK INDEX
M4740
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY Merck Index
IUPHAR
940
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
INN
2417
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
DRUG BANK
DB00988
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
CAS
51-61-6
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY
EVMPD
SUB06365MIG
Created by admin on Tue Oct 22 01:19:55 UTC 2019 , Edited by admin on Tue Oct 22 01:19:55 UTC 2019
PRIMARY